Key result
Cardiohepatic syndrome predicts ~140% higher long-term mortality in STEMI patients undergoing primary PCI.
Why the study?
Cardiohepatic syndrome reflects bidirectional heart-liver interaction, but its impact on in-hospital and long-term mortality in STEMI patients undergoing primary PCI required evaluation.
Does the presence of cardiohepatic syndrome predict in-hospital and long-term mortality in patients with STEMI undergoing primary PCI?
Cohort (n=1,541)
Does the presence of cardiohepatic syndrome predict in-hospital and long-term mortality in patients with STEMI undergoing primary PCI?
Effect estimate: HR 2.4 (95% CI 1.79-3.22)
p-value: p=<0.001
The presence of cardiohepatic syndrome is a strong independent predictor of both in-hospital and long-term mortality in STEMI patients undergoing primary PCI.
May inform prognosis in STEMI PCI patients; leaves open whether CHS is a modifiable target.
Background: Cardiohepatic syndrome (CHS) indicates a bidirectional interaction between the heart and liver. This study was designed to evaluate the impact of CHS on in-hospital and long-term mortality in patients with ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention. Materials & methods: 1541 consecutive STEMI patients were examined. CHS was defined as the elevation of at least two of three cholestatic liver enzymes: total bilirubin, alkaline phosphatase and gamma-glutamyl transferase. Results: CHS was present in 144 (9.34%) patients. Multivariate analyses revealed CHS as an independent predictor of in-hospital (odds ratio: 2.48; 95% CI: 1.42–4.34; p = 0.001) and long-term mortality (hazard ratio: 2.4; 95% CI: 1.79–3.22; p < 0.001). Conclusion: The presence of CHS is a predictor of poor prognosis in patients with STEMI and should be evaluated during the risk stratification of these patients.
No takes yet. Share an insight, caveat, or question.
Sungur et al. (2023) conducted a cohort in ST-segment elevation myocardial infarction (n=1,541). Cardiohepatic syndrome vs. Absence of cardiohepatic syndrome was evaluated on Long-term mortality (HR 2.4, 95% CI 1.79-3.22, p=<0.001). Cardiohepatic syndrome independently predicted both in-hospital (OR 2.48; 95% CI 1.42-4.34) and long-term mortality (HR 2.4; 95% CI 1.79-3.22) in STEMI patients undergoing primary PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: